1. Home
  2. ARQT vs SPRY Comparison

ARQT vs SPRY Comparison

Compare ARQT & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARQT
  • SPRY
  • Stock Information
  • Founded
  • ARQT 2016
  • SPRY 2015
  • Country
  • ARQT United States
  • SPRY United States
  • Employees
  • ARQT N/A
  • SPRY N/A
  • Industry
  • ARQT Biotechnology: Pharmaceutical Preparations
  • SPRY Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARQT Health Care
  • SPRY Health Care
  • Exchange
  • ARQT Nasdaq
  • SPRY Nasdaq
  • Market Cap
  • ARQT 1.1B
  • SPRY 1.1B
  • IPO Year
  • ARQT 2020
  • SPRY N/A
  • Fundamental
  • Price
  • ARQT $13.08
  • SPRY $12.49
  • Analyst Decision
  • ARQT Strong Buy
  • SPRY Strong Buy
  • Analyst Count
  • ARQT 5
  • SPRY 4
  • Target Price
  • ARQT $17.00
  • SPRY $26.00
  • AVG Volume (30 Days)
  • ARQT 1.9M
  • SPRY 1.4M
  • Earning Date
  • ARQT 02-25-2025
  • SPRY 03-20-2025
  • Dividend Yield
  • ARQT N/A
  • SPRY N/A
  • EPS Growth
  • ARQT N/A
  • SPRY N/A
  • EPS
  • ARQT N/A
  • SPRY N/A
  • Revenue
  • ARQT $138,708,000.00
  • SPRY $2,568,000.00
  • Revenue This Year
  • ARQT $215.24
  • SPRY $67,363.34
  • Revenue Next Year
  • ARQT $53.63
  • SPRY $511.99
  • P/E Ratio
  • ARQT N/A
  • SPRY N/A
  • Revenue Growth
  • ARQT 182.84
  • SPRY 8460.00
  • 52 Week Low
  • ARQT $5.38
  • SPRY $6.29
  • 52 Week High
  • ARQT $16.20
  • SPRY $18.51
  • Technical
  • Relative Strength Index (RSI)
  • ARQT 41.94
  • SPRY 44.57
  • Support Level
  • ARQT $13.33
  • SPRY $11.00
  • Resistance Level
  • ARQT $15.09
  • SPRY $14.87
  • Average True Range (ATR)
  • ARQT 0.86
  • SPRY 0.95
  • MACD
  • ARQT -0.16
  • SPRY 0.04
  • Stochastic Oscillator
  • ARQT 6.25
  • SPRY 31.26

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: